BioGeneration Ventures BGV IV fund closes at €140 million

BGV now one of the largest biotech investors in early stage ventures and company creation in Europe BGV IV includes new investors Eli Lilly and Company and Novo Holdings, joining existing investors Bristol Myers Squibb, European Investment Fund, Industriens Pension,...

Cristal Therapeutics announces a publication in ‘Chemical Science’ on CliCr® technology platform, comprising a new class of superior copper free click reagents for conjugation of small molecules, biologics, nanoparticles and other moieties

• Flagship chemistry journal describes the development of TMTHSI (CliCr®) as a superior click reagent • Cristal applies the CliCr® platform to the rational design of CriPec® nanomedicines, also enabling modular CriVac® vaccine product development • CliCr® can be...

Synaffix wins Best Platform Technology at 7th Annual World ADC Awards

AMSTERDAM, NETHERLANDS – September 22, 2020 – Synaffix B.V., a biotechnology companyenabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, announces thatit has won the “Best ADC Platform Technology” category at the 2020 World ADC...